MK-5475 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
86Pulmonary arterial hypertension6

86. Pulmonary arterial hypertension


Clinical trials : 1,205 Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-001108-40-GR
(EUCTR)
04/10/202113/07/2021Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial HypertensionA Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension - Phase 2/3 Study of MK-5475 in Adults with Pulmonary Arterial Hypertension Pulmonary arterial hypertension
MedDRA version: 20.0;Level: LLT;Classification code 10065150;Term: Associated with pulmonary arterial hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: MK-5475
Product Code: MK-5475
INN or Proposed INN: MK-5475
Other descriptive name: MK-5475
Product Name: MK-5475
Product Code: MK-5475
INN or Proposed INN: MK-5475
Other descriptive name: MK-5475
Product Name: MK-5475
Product Code: MK-5475
INN or Proposed INN: MK-5475
Other descriptive name: MK-5475
Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
450Phase 2;Phase 3United States;Greece;Turkey;Israel;Russian Federation;Colombia;United Kingdom;Italy;France;Mexico;Canada;Argentina;Poland;Australia;Germany;New Zealand;Sweden
2NCT04732221
(ClinicalTrials.gov)
May 19, 202127/1/2021A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Arterial HypertensionPulmonary Arterial Hypertension;Hypertension, PulmonaryDrug: MK-5475;Drug: Placebo to MK-5475Merck Sharp & Dohme LLCNULLRecruiting18 Years75 YearsAll450Phase 2/Phase 3United States;Argentina;Australia;Belgium;Canada;Colombia;France;Germany;Greece;Israel;Italy;Mexico;New Zealand;Poland;Russian Federation;Sweden;Turkey;United Kingdom
3EUCTR2020-001108-40-IT
(EUCTR)
21/04/202107/06/2021Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial HypertensionA Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension - Phase 2/3 Study of MK-5475 in Adults with Pulmonary Arterial Hypertension Pulmonary arterial hypertension
MedDRA version: 20.0;Level: LLT;Classification code 10065150;Term: Associated with pulmonary arterial hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: MK-5475
Product Code: [MK-5475]
INN or Proposed INN: MK-5475
Other descriptive name: MK-5475
Product Name: MK-5475
Product Code: [MK-5475]
INN or Proposed INN: MK-5475
Other descriptive name: MK-5475
Product Name: MK-5475
Product Code: [MK-5475]
INN or Proposed INN: MK-5475
Other descriptive name: MK-5475
MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
450Phase 2;Phase 3United States;Portugal;Turkey;Israel;Russian Federation;Colombia;United Kingdom;Italy;France;Canada;Argentina;Poland;Australia;Germany;New Zealand;Sweden
4EUCTR2020-001108-40-PL
(EUCTR)
19/04/202105/02/2021Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial HypertensionA Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension - Phase 2/3 Study of MK-5475 in Adults with Pulmonary Arterial Hypertension Pulmonary arterial hypertension
MedDRA version: 20.0;Level: LLT;Classification code 10065150;Term: Associated with pulmonary arterial hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: MK-5475
Product Code: MK-5475
INN or Proposed INN: MK-5475
Other descriptive name: MK-5475
Product Name: MK-5475
Product Code: MK-5475
INN or Proposed INN: MK-5475
Other descriptive name: MK-5475
Product Name: MK-5475
Product Code: MK-5475
INN or Proposed INN: MK-5475
Other descriptive name: MK-5475
Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
450Phase 2;Phase 3United States;Portugal;Turkey;Israel;Russian Federation;Colombia;United Kingdom;Italy;France;Canada;Argentina;Poland;Australia;Germany;New Zealand;Sweden
5EUCTR2020-001108-40-DE
(EUCTR)
08/04/202119/01/2021Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial HypertensionA Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension - Phase 2/3 Study of MK-5475 in Adults with Pulmonary Arterial Hypertension Pulmonary arterial hypertension
MedDRA version: 20.0;Level: LLT;Classification code 10065150;Term: Associated with pulmonary arterial hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: MK-5475
Product Code: MK-5475
INN or Proposed INN: MK-5475
Other descriptive name: MK-5475
Product Name: MK-5475
Product Code: MK-5475
INN or Proposed INN: MK-5475
Other descriptive name: MK-5475
Product Name: MK-5475
Product Code: MK-5475
INN or Proposed INN: MK-5475
Other descriptive name: MK-5475
Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
450Phase 2;Phase 3United States;Portugal;Greece;Turkey;Israel;Russian Federation;Colombia;United Kingdom;Italy;France;Canada;Argentina;Poland;Australia;Germany;New Zealand;Sweden
6NCT03744637
(ClinicalTrials.gov)
January 18, 201913/11/2018A Study of Single Doses of MK -5475 on Pulmonary Vascular Resistance (MK-5475-002)A Study to Assess the Effect of Single Doses of MK -5475 on Pulmonary Vascular Resistance in Patients With Moderate to Severe Pulmonary Arterial HypertensionPulmonary Arterial HypertensionDrug: MK-5475;Drug: PlaceboMerck Sharp & Dohme Corp.NULLCompleted18 Years70 YearsAll25Phase 1Moldova, Republic of